(MOR yoo ate SOW dee um)
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Scleromate: 5% (30 mL)
Generic: 5% (30 mL [DSC])
Brand Names: U.S.
- Sclerosing Agent
Morrhuate sodium causes inflammation of the vein's intima resulting in the formation of a thrombus. Occlusion secondary to the fibrous tissue and the thrombus results in the obliteration of the vein.
Use: Labeled Indications
Treatment of small, uncomplicated varicose veins of the lower extremities
Hypersensitivity to morrhuate sodium or any component of the formulation; arterial disease; acute thrombophlebitis; valvular or deep vein incompetence; bedridden patients; varicosities caused by abdominal or pelvic tumors; patients with systemic diseases (eg, uncontrolled diabetes mellitus, thyrotoxicosis, tuberculosis, neoplasms, asthma, sepsis, blood dyscrasias, and acute respiratory or skin diseases); continued administration following a systemic reaction or an unusual local reaction at the injection site; extensive therapy in severely debilitated or senile patients
Note: A test dose of 0.25-1 mL of a 5% injection may be given (into a varicosity) 24 hours before full-dose treatment.
Full-dose treatment: 50-250 mg, depending on the size and degree of varicosity (50-100 mg for small or medium veins, 150-250 mg for large veins); may be given as multiple injections at one time or in single doses.
Dosage adjustment in renal impairment: No dosage adjustment provided in manufacturer’s labeling.
Dosage adjustment in hepatic impairment: No dosage adjustment provided in manufacturer’s labeling.
For IV injection into varicose vein only; avoid extravasation. Use only clear solutions; solution should become clear when warmed. Solution froths easily; use a large bore needle to fill syringe and a small bore needle for injection. Warm solutions with hot water prior to injection into small vein, if solution is cold, or if the solid matter has separated in the solution.
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).
There are no known significant interactions.
Frequency not defined.
Cardiovascular: Thrombosis, vascular collapse
Central nervous system: Dizziness, drowsiness, headache
Gastrointestinal: Nausea, vomiting
Local: Burning or cramping at the site of injection, severe extravasation effects
Neuromuscular & skeletal: Weakness
Respiratory: Asthma, pulmonary embolism, respiratory depression
Miscellaneous: Anaphylaxis, hypersensitivity reactions
Concerns related to adverse effects:
• Anaphylactic/hypersensitivity reactions: Anaphylactic and hypersensitivity reactions (eg, asthma, nausea, vomiting, respiratory depression, urticaria, vascular collapse) have occurred. Immediate treatment (including epinephrine, antihistamines, corticosteroids) should be available.
• Extravasation: Sloughing and necrosis of tissue may occur following extravasation.
• Infections: Delay therapy in patients with acute local or systemic infections (eg, infected ulcers).
• Local reactions: Burning or cramping sensations may occur following administration.
• Appropriate use: Valvular and venous competency should be evaluated prior to use.
• Experienced physician: This drug should only be administered by a physician familiar with proper injection techniques.
• Test dose: A test dose of 0.25-1 mL of a 5% injection may be given 24 hours before full-dose treatment.
Prior to use, evaluate valvular competency and deep vein patency/competency by angiography and/or by clinical tests (eg, Trendelenburg or Perthes).
Pregnancy Risk Factor
Animal reproduction studies have not been conducted.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience short-term pain, skin discoloration, or headache. Have patient report immediately to prescriber angina, hemoptysis, dyspnea, or injection site pain or irritation (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.